Health Care·Biotechnology·$3.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | -50.49% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.62 | N/A | -50.49% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a commitment to their research and development efforts. They acknowledged the difficulties but did not provide specific future expectations.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its pipeline despite the current challenges.
Denali Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may leave investors uncertain about the company's near-term prospects. The stock's reaction indicates cautious sentiment among investors following the earnings report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DT MIDSTREAM INC
Feb 25, 2022